At the 23rd Annual European Association of Urology (EAU) Congress, results were presented which added evidence that Levitra® (vardenafil HCI) works very well in men with dyslipidemia.[1] The double-blind, placebo-controlled trial in about 400 men showed that Levitra® significantly improved the ability of men with erectile dysfunction (ED) and high cholesterol, to achieve and maintain an erection for successful sexual intercourse.[2] 
GlaxoSmithKline reported its 2007 global giving to charitable initiatives totalled £282 million, equivalent to almost 4% of pre-tax profits for the company (with the FTSE 100 average around 1%). Donations of albendazole treatments for the company's flagship programme to eliminate Lymphatic Filariasis (commonly known as elephantiasis) were valued at £14 million, bringing the total number of treatments given since GSK made its commitment 10 years ago to almost 750 million. 
Pfizer Inc said today that the Federal Court of Appeal of Canada has reversed a lower court ruling that held that Pfizer's enantiomer patent could not block generic manufacturer Ranbaxy Laboratories Limited from obtaining approval for a competitor product to Lipitor. The appellate court issued an order prohibiting regulatory approval of Ranbaxy's product in Canada until Pfizer's enantiomer (calcium salt) patent - Canadian Patent No. 2,021,546 - expires in July 2010. Bayer Schering Pharma AG has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending Zevalin® ([90Y]-ibritumomab tiuxetan) as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma (FL) in Europe. 
Genzyme Corp. (Nasdaq: GENZ) announced the withdrawal of the European application to extend the Evoltra® (clofarabine) product label to include the treatment of elderly patients with acute myeloid leukemia (AML). This application and the data on which it was based were filed by Bioenvision, Ltd. before the company was acquired by Genzyme last year. GlaxoSmithKline (GSK) notes the conclusions announced by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding its investigation into disclosure of paediatric trial data for the anti-depressant medicine Seroxat (paroxetine). 